COMPANY

Veloxis Pharmaceuticals

Status: Acquired, now part of Asahi Kasei Therapeutics · How status works

Keywords: renal infectious disease infectious diseases Renal Failure Chemotherapy-induced Peripheral Neuropathy Dyslipidemia Liver Failure Kidney Transplantation Autoimmune Hepatitis Tremors Kidney Failure VEL-101 thrombomodulin alfa LCP-AtorFen

Profile checked Oct 10, 2026

18Trials (company is sponsor)

Timeline

Aug 18, 2026 Trial start Phase 2: VEL-101 to Prevent Rejection After Kidney Transplantation source ↗
Apr 26, 2022 Trial start Phase 1: A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 source ↗
Mar 24, 2022 Trial start Phase 1: Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients source ↗
2021-10 Trial start Phase 2: A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo source ↗
2015-01 Trial start Phase 3: Pharmacokinetic Comparison Of All FK-506 Formulations source ↗
2013-11 Trial start Phase 3: Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily. source ↗
2012-11 Trial start Phase 2: Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant source ↗
2011-12 Trial start Phase 3: Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) source ↗
2010-09 Trial start Phase 3: Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx source ↗
2008-12 Trial start Phase 3: Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily source ↗
2008-10 Trial start Phase 2: Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients source ↗
2008-09 Trial start Phase 2: Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients source ↗
2007-12 Trial start Phase 2: LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis source ↗
2007-11 Trial start Phase 2: Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients source ↗
2007-10 Trial start Phase 2/Phase 3: 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia source ↗
2007-07 Trial start Phase 2: Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia source ↗
2007-07 Trial start Phase 2: Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients source ↗

Upcoming milestones

2028-10 (ESTIMATED) · Phase 2 · VEL-101 to Prevent Rejection After Kidney Transplantation · NCT07290777

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 18

Record	Title	Phase	Status	Start	Primary completion
NCT07290777	VEL-101 to Prevent Rejection After Kidney Transplantation	Phase 2	Recruiting	Aug 18, 2026	2028-10 (estimated)
NCT05251727	Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients	Phase 1	Terminated	Mar 24, 2022	Jun 5, 2024 (actual)
NCT05238493	A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101	Phase 1	Completed	Apr 26, 2022	Jan 3, 2023 (actual)
NCT04492436	A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo	Phase 2	Withdrawn	2021-10	2023-04 (estimated)
NCT00664859	12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia	Phase 2/Phase 3	Completed	2007-10	2009-02 (actual)
NCT00608894	LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis	Phase 2	Terminated	2007-12	2009-04 (actual)
NCT00504829	Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia	Phase 2	Completed	2007-07	2008-02 (actual)
NCT01962922	Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.	Phase 3	Completed	2013-11	2015-07 (actual)
NCT01187953	Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx	Phase 3	Completed	2010-09	2013-03 (actual)
NCT02411604	Expanded Access Study for Renal Transplant Patients With Envarsus XR ™	Not listed	Approved for marketing	Not listed	Not listed
NCT02339246	Pharmacokinetic Comparison Of All FK-506 Formulations	Phase 3	Completed	2015-01	2015-03 (actual)
NCT01438710	Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)	Phase 3	Completed	2011-12	2012-08 (actual)
NCT00817206	Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily	Phase 3	Completed	2008-12	2011-02 (actual)
NCT00608244	Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients	Phase 2	Completed	2007-11	2008-06 (actual)
NCT00496483	Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients	Phase 2	Completed	2007-07	2008-03 (actual)
NCT01666951	Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant	Phase 2	Completed	2012-11	2013-03 (actual)
NCT00772148	Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients	Phase 2	Completed	2008-10	2010-05 (actual)
NCT00765661	Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients	Phase 2	Completed	2008-09	2010-02 (actual)